|
Age (years), mean (SD)
|
63.2 (6.1)
|
|
Pre-op PSA (ng/mL), mean (SD)
|
12.8 (15.5)
|
|
Clinical tumor stage, n (%)
| |
|
T1
|
73 (32.5)
|
|
T2
|
142 (63.1)
|
|
T3
|
5 (2.2)
|
|
NA
|
5 (2.2)
|
|
Gleason score, n (%)
| |
|
≤6
|
92 (40.9)
|
|
7
|
93 (41.3)
|
|
≥8
|
40 (17.8)
|
|
Pathological stage, n (%)
| |
|
pT2a
|
7 (3.1)
|
|
pT2b
|
3 (1.3)
|
|
pT2c
|
60 (26.7)
|
|
pT3a
|
100 (44.4)
|
|
pT3b
|
55 (24.4)
|
|
Margin status, n (%)
| |
|
0 (negative)
|
71 (31.6)
|
|
1 (positive)
|
154 (68.4)
|
|
Nodal status, n (%)
| |
|
N0
|
186 (82.7)
|
|
N1
|
39 (17.3)
|
|
High risk score (pT3N + M+), n (%)
| |
|
0
|
32 (14.2)
|
|
1
|
192 (85.8)
|
|
NA
|
1 (0.0)
|
|
Biochemical recurrence, n (%)
| |
|
No
|
119 (52.9)
|
|
Yes
|
106 (47.1)
|
|
Death by prostate cancer, n (%)
| |
|
No
|
215 (95.6))
|
|
Yes
|
10 (4.4)
|
|
Death by other causes, n (%)
| |
|
No
|
191 (84.9))
|
|
Yes
|
34 (15.1)
|
|
Death – all causes, n (%)
| |
|
No
|
181 (80.4)
|
|
Yes
|
44 (19.6)
|
|
Time to BCR (years), mean (SD)
|
6.8 (4.5)
|
|
Time to DPCa (years), mean (SD)
|
10.6 (3.1)
|
